骨髓增生性疾病药物市场－全球产业规模、份额、趋势、机会和预测，按类型、药物类型、给药途径、配销通路、地区和竞争格局划分，2020-2030年预测

全球骨髓增生性疾病药物市场规模预计将从2024年的99.4亿美元成长至2030年的140.6亿美元，复合年增长率（CAGR）为5.95%。骨髓增生性疾病（MPD）药物是专门用于治疗一组由骨髓干细胞异常增生引起的慢性血液系统恶性肿瘤的药物，这些肿瘤会导致血球过度生成。市场扩张的主要驱动力是全球MPD盛行率的不断上升，而人口老化是导致盛行率上升的重要因素。此外，分子诊断技术的进步也使得疾病的早期和精准识别成为可能。

主要市场驱动因素

全球骨髓增生性疾病药物市场主要受两大驱动因素影响：骨髓增生性疾病盛行率的不断上升以及新型疗法研发的持续进步。发病率的上升和需要持续治疗的患者群体不断扩大，大大促进了市场扩张。

主要市场挑战

全球骨髓增生性疾病药物市场扩张的一大挑战是先进疗法的高昂费用。这一经济障碍直接限制了患者获得关键治疗的机会，尤其是在医疗资源匮乏的地区，从而限制了市场的整体成长潜力。

主要市场趋势

在全球骨髓增生性疾病药物市场中，对标靶疗法的日益关注是一个显着趋势，这主要得益于精准医疗的发展趋势。这种疗法研发的药物能够选择性地干扰对癌细胞生长和存活至关重要的特定分子通路，从而与传统疗法相比，提供更高的疗效和更佳的安全性。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球骨髓增生性疾病药物市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（原发性骨髓纤维化、真性红血球增多症增多症、原发性血小板增多症、嗜酸性粒细胞增多症、系统性肥大细胞增多症）
  • 依药物类型（JAK2抑制剂、抗肿瘤药、去甲基化剂、甲磺酸伊马替尼、其他）
  • 依给药途径（口服、父母给药、其他）
  • 依配销通路（医院药局、零售店、药局）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美骨髓增生性疾病药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲骨髓增生性疾病药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区骨髓增生性疾病药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲骨髓增生性疾病药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲骨髓增生性疾病药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球骨髓增生性疾病药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• AbbVie, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc

第十六章：策略建议

第17章调查会社について・免责事项

The Global Myeloproliferative Disorders Drugs Market will grow from USD 9.94 Billion in 2024 to USD 14.06 Billion by 2030 at a 5.95% CAGR. Myeloproliferative Disorders (MPDs) drugs comprise a specialized pharmaceutical segment focused on treating a group of chronic hematological malignancies stemming from aberrant bone marrow stem cell proliferation, leading to an overproduction of blood cells. The market's expansion is primarily propelled by the increasing global prevalence of MPDs, which is significantly influenced by an aging demographic, alongside advancements in molecular diagnostics that enable earlier and more precise disease identification.

Key Market Drivers

The Global Myeloproliferative Disorders Drugs Market is significantly influenced by two primary drivers: the increasing prevalence of myeloproliferative disorders and continuous advancements in the research and development of novel therapies. The rising incidence and growing patient populations requiring ongoing management contribute substantially to market expansion.

Key Market Challenges

A notable challenge impeding the expansion of the Global Myeloproliferative Disorders Drugs Market is the substantial cost associated with advanced therapies. This financial barrier directly limits patient access to critical treatments, particularly within underserved regions, thereby restricting the overall growth potential of the market. High treatment expenses create a significant economic burden for patients and healthcare systems alike, often resulting in delayed or foregone treatment initiation and compromised adherence.

Key Market Trends

The increasing focus on targeted therapies represents a significant trend in the Global Myeloproliferative Disorders Drugs Market, driven by the shift towards precision medicine. This approach develops drugs that selectively interfere with specific molecular pathways crucial for the growth and survival of cancer cells, thereby offering enhanced efficacy and a more favorable safety profile compared to conventional treatments.

Key Market Players

• AbbVie, Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc

Report Scope:

In this report, the Global Myeloproliferative Disorders Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myeloproliferative Disorders Drugs Market, By Type:

• Primary Myelofibrosis
• Polycythemia Vera
• Essential Thrombocythemia
• Hyper eosinophilic Syndrome
• Systemic Masto cytosis

Myeloproliferative Disorders Drugs Market, By Drug Type:

• JAK2 Inhibitors
• Anti-Neoplastics
• Demethylation Agents
• Imatinib Mesylate
• Others

Myeloproliferative Disorders Drugs Market, By Route of Administration:

• Oral
• Parental
• Others

Myeloproliferative Disorders Drugs Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Stores
• Drug Stores

Myeloproliferative Disorders Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Myeloproliferative Disorders Drugs Market.

Available Customizations:

Global Myeloproliferative Disorders Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myeloproliferative Disorders Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Hyper eosinophilic Syndrome, Systemic Masto cytosis)
  • 5.2.2. By Drug Type (JAK2 Inhibitors, Anti-Neoplastics, Demethylation Agents, Imatinib Mesylate, Others)
  • 5.2.3. By Route of Administration (Oral, Parental, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Stores, Drug Stores)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Myeloproliferative Disorders Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Myeloproliferative Disorders Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Myeloproliferative Disorders Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Myeloproliferative Disorders Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Myeloproliferative Disorders Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Myeloproliferative Disorders Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Myeloproliferative Disorders Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Myeloproliferative Disorders Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Myeloproliferative Disorders Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Myeloproliferative Disorders Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Myeloproliferative Disorders Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Myeloproliferative Disorders Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Myeloproliferative Disorders Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Myeloproliferative Disorders Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Myeloproliferative Disorders Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Myeloproliferative Disorders Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Myeloproliferative Disorders Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Novartis AG
• 15.4. AstraZeneca PLC
• 15.5. Johnson and Johnson Services, Inc.
• 15.6. Sun Pharmaceutical Industries Ltd.
• 15.7. Hikma Pharmaceuticals PLC
• 15.8. Teva Pharmaceutical Industries Ltd.
• 15.9. Pfizer Inc.
• 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer